Alpha-Synuclein Antibody Therapeutics

Alpha-synuclein is an integral component of Lewy bodies which are comprised of protein clumps and are a pathological hallmark of Parkinson’s disease. They have also been detected in several other neurodegenerative diseases, known as synucleopathies. Here is the latest research on alpha-synuclein antibody therapeutics.

December 13, 2018
Review

Emerging Immunotherapies for Parkinson Disease

Neurology and Therapy
Samis M A ZellaLars Tönges
June 20, 2019
Review
Open Access

The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration

Frontiers in Immunology
Taxiarchis KatsinelosWilliam A McEwan
June 25, 2020
Open Access

Parkinson's disease: etiopathogenesis and treatment

Journal of Neurology, Neurosurgery, and Psychiatry
Joseph Jankovic, Eng King Tan
June 25, 2020

The Effect of (-)-Epigallocatechin-3-Gallate on the Amyloid-β Secondary Structure

Biophysical Journal
Atanu AcharyaVictor S Batista
July 11, 2018
Open Access

Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Ana I Rodriguez-PerezJose L Labandeira-Garcia
May 21, 2019
Review

Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases

Journal of Pharmacological Sciences
Masahiro NishiboriHideo K Takahashi
September 12, 2019
Open Access

Encoding the Sequence of Specific Autoantibodies Against beta-Amyloid and alpha-Synuclein in Neurodegenerative Diseases

Frontiers in Immunology
Alexandra AlbusRichard Dodel
February 15, 2017
Open Access

O-GlcNAcylation of α-Synuclein at Serine 87 Reduces Aggregation without Affecting Membrane Binding

ACS Chemical Biology
Yuka E LewisMatthew R Pratt
January 8, 2020

Current Status and Future Prospects of Therapeutic Development of Parkinson's Disease

Brain and nerve = Shinkei kenkyū no shinpo
Hideki Mochizuki
February 10, 2020
Review

Emerging Disease-modifying Strategies Targeting α-synuclein in Parkinson's Disease

Brain and nerve = Shinkei kenkyū no shinpo
Takafumi HasegawaShun Ishiyama
March 8, 2018
Case Report
Open Access

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

Journal of Neurology
E C TallantyreA Jacob
August 30, 2018
Open Access

Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model

NPJ Parkinson's Disease
Diptaman ChatterjeeJeffrey H Kordower
April 22, 2017
Open Access

Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice

Oncotarget
Laurie RanganOlivier Adotévi
April 18, 2020
Review
Open Access

Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Congcong ZhangAndrea L J Marschall
April 8, 2018

Biophysical Properties and Heating-Induced Aggregation of Lysine-Conjugated Antibody-Drug Conjugates

Journal of Pharmaceutical Sciences
Aditya V GandhiJohn F Carpenter
May 6, 2019
Review
Open Access

Antibodies against alpha-synuclein: tools and therapies

Journal of Neurochemistry
Nishant N VaikathOmar M A El-Agnaf
October 31, 2018

Mesenchymal Stem Cell-Derived Exosomes Reduce A1 Astrocytes via Downregulation of Phosphorylated NFκB P65 Subunit in Spinal Cord Injury

Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
Lin WangYanjie Jia

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/alpha-synuclein-antibody-therapeutics/e207b8e1-e488-47b2-9296-d3e42af9c5b8